Kenvue Inc. (KVUE) EPS CAGR:-7.53%(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over longer horizons, Kenvue Inc.'s EPS CAGR averages -8.55% over 3 years and 0.22% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how Kenvue Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
KVUE EPS CAGR Chart
Kenvue Inc. (KVUE)
KVUE Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 14 quarters.
KVUE EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $0.54 | $0.77 | +$0.23 | +42.59% | +42.59% |
| 2024 | $0.90 | $0.54 | $-0.36 | -40.00% | -40.00% |
| 2023 | $1.08 | $0.90 | $-0.18 | -16.67% | -16.67% |
| 2022 | $1.10 | $1.08 | $-0.02 | -1.82% | -1.82% |
| 2021 | $-0.47 | $1.10 | +$1.57 | N/A | N/A |
| 2020 | $0.76 | $-0.47 | $-1.23 | -161.84% | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $0.25 | +47.1% | +47.1% |
| Q4 2025 | $0.17 | -19.0% | +13.3% |
| Q3 2025 | $0.21 | -4.5% | +5.0% |
| Q2 2025 | $0.22 | +29.4% | +626.1% |
| Q1 2025 | $0.17 | +13.3% | +13.3% |
| Q4 2024 | $0.15 | -25.0% | -11.8% |
| Q3 2024 | $0.20 | +560.1% | -13.0% |
| Q2 2024 | $0.03 | -79.8% | -86.2% |
| Q1 2024 | $0.15 | -11.8% | -44.4% |
| Q4 2023 | $0.17 | -26.1% | -19.2% |
| Q3 2023 | $0.23 | +4.5% | -32.4% |
| Q2 2023 | $0.22 | -18.5% | -31.3% |
| Q1 2023 | $0.27 | +28.4% | -3.6% |
| Q4 2023 | $0.21 | -38.1% | -4.4% |
| Q3 2022 | $0.34 | +6.3% | — |
| Q2 2022 | $0.32 | +14.3% | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry